- Home
- AGPU vs ATRA Comparison
AGPU vs ATRA Comparison
Compare AGPU & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AGPU | ATRA |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 81.2M |
| IPO Year | 2008 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AGPU | ATRA |
|---|---|---|
| Price | $10.68 | $9.36 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 561.9K | 50.1K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | ★ N/A | N/A |
| Revenue | $125,284.00 | ★ $120,772,000.00 |
| Revenue This Year | $12,476.23 | N/A |
| Revenue Next Year | $55.17 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.03 | $3.92 |
| 52 Week High | $10.92 | $19.15 |
Technical Indicators
Market Signals| Indicator | AGPU | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 64.17 | 56.62 |
| Support Level | $6.26 | $9.03 |
| Resistance Level | $10.86 | $11.17 |
| Average True Range (ATR) | 1.02 | 0.70 |
| MACD | 0.24 | 0.15 |
| Stochastic Oscillator | 88.39 | 83.08 |
Price Performance
Historical ComparisonAbout AGPU Axe Compute Inc. Common Stock
Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, the company aims to provide access to bare-metal GPUs at scale for both emerging and established organizations.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.